戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 2019 infection has been high rates of venous thromboses.
2 o 0.95) and 0.76 (0.73 to 0.79) for arterial thromboses.
3 e of insulin resistance; there were no graft thromboses.
4 increased the risk of AMI, but not the other thromboses.
5 o 0.99) and 0.72 (0.70 to 0.75) for arterial thromboses.
6  the cost of an increased risk of late stent thromboses.
7 n morbidity and mortality, mainly because of thromboses.
8 ary embolism, atrial arrhythmias, and venous thromboses.
9 had intracerebral hemorrhage; 8 had non-CVST thromboses.
10 ents with rapidly progressive multiple organ thromboses.
11                      Only 4 patients died of thromboses.
12 ment similar to more proximal or symptomatic thromboses.
13 oss on the machine or postoperative vascular thromboses.
14 urring significantly earlier than peripheral thromboses.
15 yocardial infarction in analyses of arterial thromboses.
16 riant received transfusions, and 2 developed thromboses.
17 ther conditions associated with pathological thromboses.
18 rovascular aneurysms, or arterial and venous thromboses.
19 atment with heparin resulting in paradoxical thromboses.
20 s of heart disease are at increased risk for thromboses.
21  ability to inhibit both venous and arterial thromboses.
22 ved to influence the development of arterial thromboses.
23 ology of rejection characterized by vascular thromboses.
24 elet reactivity with a resulting increase in thromboses.
25 urred in 8 pts (23.5%): 4 bleeding, 3 portal thromboses (1 complete, 2 partial), and 1 sepsis.
26  the fish oil group, there were half as many thromboses (1.71 vs 3.41 per 1000 access-days; IRR, 0.50
27 perior in the prevention of catheter-related thromboses (13 [3%] vs 34 [7%]; 0.38, 0.20-0.71, p=0.002
28 tenoses, one dissection), 185 in the EIA (17 thromboses, 167 stenoses, one dissection), one in the co
29 ases (57%): 10 venous thromboses, 3 arterial thromboses, 2 combined arterial and venous thrombosis, 2
30  did not reduce the rate of catheter-related thromboses (24 [6%] vs 24 [6%]; relative risk 0.99, 95%
31                  FvQ/Q mice formed occlusive thromboses 27+/-3 minutes (n=7) after the onset of injur
32                            Thirty-four major thromboses (3 fatal) and 14 major hemorrhages (none fata
33 ke (2.44 [1.04-5.75], p = 0.04) and arterial thromboses (3.49 [0.97-12.54], p = 0.05).
34 was compromised in 20 cases (57%): 10 venous thromboses, 3 arterial thromboses, 2 combined arterial a
35 pulmonary embolisms (42.2%), and deep venous thromboses (34.5%).
36              A clinically significant HAC (4 thromboses, 35 HACs requiring IVI) was found in 2.9% (n
37 imultaneous patients had more renal vascular thromboses (4.4% vs 1.3% tx alone, 0% pre; P = 0.04).
38  intimal dissections, 11 pseudoaneurysms, 17 thromboses, 4 carotid cavernous fistulas, and 1 transect
39  arrythmias (6.44, 4.17 to 9.96), and venous thromboses (5.43, 3.27 to 9.01).
40 , because of a higher proportion of arterial thromboses (6.2% vs 3.7%; P = .015).
41             In those with pulmonary arterial thromboses, 93% were identified incidentally on first sc
42  A risk-benefit analysis found 3 fewer stent thromboses (95% CI: 2 to 5) and 6 fewer MIs (95% CI: 2 t
43 thromboses after ChAdOx1-S, and for arterial thromboses after both vaccines.
44 vents were higher at younger ages for venous thromboses after ChAdOx1-S, and for arterial thromboses
45 rombocytopenia and major arterial and venous thromboses after COVID-19 vaccination.
46 n England, there were 260 279 first arterial thromboses and 59 421 first VTEs during 41.6 million per
47 his was accompanied by more pulmonary artery thromboses and adherent hMSCs found on explanted oxygena
48 ts to proximal pulmonary arterial aneurysms, thromboses and calcification; to truncal valve stenosis
49  ischemic stroke comprise the major arterial thromboses and deep-vein thrombosis and pulmonary emboli
50                        Reports of widespread thromboses and disseminated intravascular coagulation (D
51 r mediated pathways leading to microvascular thromboses and endothelial activation appear to play an
52 disorders featuring anticoagulant-refractory thromboses and intermittent thrombocytopenia that were a
53                       A combined endpoint of thromboses and major bleeding showed no difference betwe
54 ies are at risk for major abdominal vascular thromboses and organ infarction.
55  symptoms to life-threatening events such as thromboses and strokes.
56  Furthermore, many isolated distal deep vein thromboses and subsegmental pulmonary emboli are identif
57 d ratios comparing the incidence of arterial thromboses and venous thromboembolic events (VTEs) after
58 ole-population increases in risk of arterial thromboses and VTEs 49 weeks after COVID-19 diagnosis we
59 wasaki disease patients with coronary artery thromboses and/or myocardial infarctions).
60  to 1.05) and 0.58 (0.53 to 0.63) for venous thromboses, and 0.90 (0.86 to 0.95) and 0.76 (0.73 to 0.
61  to 0.88) and 0.57 (0.53 to 0.62) for venous thromboses, and 0.94 (0.90 to 0.99) and 0.72 (0.70 to 0.
62 7%) were non-catheter-associated deep venous thromboses, and 9 (0.6%) were pulmonary emboli.
63 ythropoiesis and granulopoiesis, more venous thromboses, and a higher rate of polycythaemic transform
64                                              Thromboses are a serious complication in patients with s
65                          Arterial and venous thromboses are classically considered distinct disease s
66 but catheter occlusions and catheter-related thromboses are common complications that can result from
67  treatment of central venus catheter-related thromboses are critical in the treatment of patients req
68                                              Thromboses are detected frequently around the time of on
69                                        Other thromboses are found on non-ruptured but inflamed plaque
70                          Arterial and venous thromboses are the most significant complications in pat
71                             Catheter-related thromboses are usually diagnosed by Doppler ultrasonogra
72               Gender differences in vascular thromboses are well known, and there is evidence that pl
73  thrombocytopenic purpura and other arterial thromboses associated with compromised VWF proteolysis.
74 ring revision of TIPS with one to five prior thromboses at 1 day to 1 year after initial TIPS formati
75 nted with Fv+/+ bone marrow formed occlusive thromboses at 35+/-5 minutes (n=7, P<0.05 compared with
76 AMTS-13 activity, and VWF-rich microvascular thromboses at autopsy.
77         Five patients (33%) developed venous thromboses at the central catheter tip.
78                                     Vascular thromboses, bowel perforation, septicemia, and retranspl
79  prevent CVC infections and catheter-related thromboses, but confirmatory studies and cost-effectiven
80                             Catheter-related thromboses can lead to catheter infection, pulmonary emb
81                  Failure to detect and treat thromboses can result in mesenteric ischemia, chronic ca
82 inding in human VCA, consisting of capillary thromboses (CT) in the upper dermis.
83    In some rare cases, cerebral venous sinus thromboses (CVST) have been reported as a severe side ef
84                    No inhibitor development, thromboses, deaths, or persistent changes in liver-funct
85                   An uncomplicated deep vein thromboses developed in one patient with a history of re
86                                              Thromboses developed in six of 240 flaps (2.5%): 4 were
87 mboli (PE) in cancer patients with deep vein thromboses (DVT) was reviewed to identify indications, p
88            The primary outcome was deep vein thromboses (DVTs) averted.
89 enous (21%), and five (7%) systemic arterial thromboses/end-organ embolic complications.
90 mia should undergo ultrasonography to detect thromboses even if the physical examination is normal.
91 h late portal vein or vena caval stenoses or thromboses from a cohort of 524 grafts with survival gre
92        Two patients with symptoms of in situ thromboses had a higher percentage of adherent cells com
93 ocytopenia (HIT) develop clinically apparent thromboses (HITT) remains uncertain.
94 such as haemodynamic compromise, infections, thromboses, impaired growth and kidney failure.
95  among patients without thrombosis; among 40 thromboses in 40 patients who did not undergo transplant
96 and comparable between groups, with no stent thromboses in any group at 6 months.
97 rent CAPS characterized by multiple arterial thromboses in large and small vessels despite maximal an
98 ion in symptomatic catheter-related or other thromboses in patients with cancer and therefore we shou
99  common and distinct features of portal vein thromboses in patients without liver tumors, with and wi
100 population there were 22 (16.5%) episodes of thromboses in the fondaparinux group and 13 (21.4%) in t
101 om 6 months to 3 years there were more stent thromboses in the Taxus group (hazard ratio 0.19 [95% co
102 e confirmed in 66 patients; an additional 36 thromboses in unique devices were suspected.
103                                              Thromboses in unusual locations after the Coronavirus Di
104                                 Other venous thromboses include catheter- and circuit-associated in p
105            Risk factors for catheter-related thromboses include previous catheter infections, malposi
106               Prevention of catheter-related thromboses includes proper positioning of the CVC and pr
107 ), pulmonary embolism (n = 32), other venous thromboses (including deep vein thrombosis) (n = 42), an
108          Twenty-two (52%) had major vascular thromboses, including those in the inferior vena cava (n
109      The blood flow inside a tube with multi-thromboses is mathematically investigated.
110                                              Thromboses limited to infrapopliteal leg deep veins (iso
111 at post-TPIAT thrombocytosis and portal vein thromboses may be linked to the islet infusion inflammat
112 ocardial infarction (n = 34), other arterial thromboses (n = 26), pulmonary embolism (n = 32), other
113 s (8 FC and 2 placebo) exhibited 12 possible thromboses; none were clearly related to FC.
114          Only 4 of 27 (14.8%) of portal vein thromboses occurred at platelet counts 500 x 109/L.
115                  No deaths, malignancies, or thromboses occurred during the trial.
116                                        Stent thromboses occurred in 1 patient assigned to placebo <24
117                           Two maternal valve thromboses occurred.
118 urred in 12.2% of patients, with portal vein thromboses occurring significantly earlier than peripher
119 win sister, who was diagnosed with extensive thromboses of the inferior vena cava, portal vein, and h
120 s, 3 had pulmonary embolism, and 4 had other thromboses; of these patients, 6 died.
121 vents per 100 patient-years) compared with 2 thromboses on eculizumab (0.8 events per 100 patient-yea
122 These studies demonstrate markedly increased thromboses on stents with blood isolated from HPA Tg mic
123 fold group had definite or probable scaffold thromboses (one definite acute, one definite sub-acute,
124 -risk groups such as those with prior venous thromboses or coexistent defects of anticoagulation and
125  32-65 years; mean age, 42 years), abdominal thromboses or ischemic events were detected at CT.
126        Venous thrombotic events (deep venous thromboses or pulmonary emboli) were documented and conf
127  with an mRNA COVID-19 vaccine developed new thromboses or relevant increase in anti-PF4/heparin IgG
128 factors [HRF] (multiple arteriovenous access thromboses, prior deep vein thrombosis, prior allograft
129                                  Portal vein thromboses (PVTs) are common in patients with cirrhosis
130 s risk factors in patients with a history of thromboses; red cell binding sites on endothelial cells
131 asis, but its effects across the spectrum of thromboses remain poorly understood.
132 een questions if these small or asymptomatic thromboses require anticoagulation management similar to
133              The existence of these multiple thromboses restricts the blood flow in this tube and the
134 2 combined arterial and venous thrombosis, 2 thromboses secondary to allograft pancreatitis, and 3 ca
135 tiple vessel-related complications including thromboses, stenoses, occlusions, and aneurysms.
136    There were no instances of graft vascular thromboses/stenoses/leaks (0%).
137                Besides CVST, splanchnic vein thromboses (SVT) and other thromboembolic events have be
138 diagnosis declines more rapidly for arterial thromboses than VTEs.
139 view of CT scans revealed more grade 1 and 2 thromboses than were initially reported.
140 and bind platelets, forming microvasculature thromboses that cause ischemic organ injury (eg, myocard
141 atient with a history of recurrent deep vein thromboses that had no adverse effect on her outcome.
142 ght heparin was instituted to prevent venous thromboses, the combination regimen was well tolerated.
143  hepatic artery stenoses, six hepatic artery thromboses, two hepatic artery pseudoaneurysms, two sple
144 3-4 pancreatitis, central neurotoxicity, and thromboses was 12%, 4%, and 6%, respectively, and not as
145                                        Stent thromboses were also assessed.
146                                  Portal vein thromboses were associated with infused islet volumes an
147                           A total of 72 pump thromboses were confirmed in 66 patients; an additional
148                                Main sites of thromboses were deep veins of the extremities (10 of 23;
149                                 Breakthrough thromboses were rare, although anticoagulant prophylaxis
150 uary 2008 and September 2013, 26 (0.61%) THV thromboses were reported out of 4266 patients undergoing
151                                No late stent thromboses were seen in any treated group despite clopid
152                                 The multiple thromboses with increasing heights are evident in stream
153 passing treatment of any unknown concomitant thromboses with only low risk for hemorrhage.
154  symptoms, vasomotor symptoms, and deep vein thromboses with tamoxifen.
155                      There were no deep vein thromboses, with 1 superfificial venous thrombosis in ea

 
Page Top